Normobaric hyperoxia preconditioning ameliorates cisplatin nephrotoxicity.
BACKGROUND
Cisplatin is a potent anticancer drug, but its nephrotoxicity limits the clinical use of it. To reduce the Cisplatin-induced nephrotoxicity, various interventions have been implicated. The aim of this study was to examine whether preconditioning with normobaric hyperoxia would prevent Cisplatin-induced nephrotoxicity in patient with solid tumor.


METHODS
In a prospective study, 80 adult patients with solid tumor who were treated with Cisplatin between February 2011 and December 2011 were included. Forty-three patients were exposed to pure oxygen via non-rebreathing reservoir mask which increased the provided oxygen rate to 60% oxygen for 2 hours at 48, 24, and 6 hours before intravenous administration of Cisplatin and 37 patients received only Cisplatin as a control group. Estimated glomerular filtration rate (eGFR) calculated in all patients on day 1 before and on days 1, 3, 6, 30 after Cisplatin exposures.


RESULTS
Patients treated with Cisplatin and 60% oxygen showed a mild improvement in eGFR and mild reduction of serum creatinine after 30 days with statistically mild significant differences (p = 0.048).


CONCLUSIONS
This study showed that normobaric and intermittent precondition of 60% oxygen prior to Cisplatin treatment had an acute transient adverse effect on renal function; however, the improvement of renal function will be seen after 30 days. Thus, it may help to prevent Cisplatin nephrotoxicity.
Department of Hematology & Oncology, Baghiyatallah University of Medical Sciences , Tehran , Iran .
Alireza
A
Saadat
Somayeh Sadat
SS
Shariat Maghani
Zohreh
Z
Rostami
Amir
A
Davoudi
Farnoush
F
Davoudi
Alireza
A
Shafie
Behzad
B
Eynollahi
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018496:Hyperoxia / Q000378:metabolism / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000627:therapeutic use*; D011446:Prospective Studies
D000970:Antineoplastic Agents; D002945:Cisplatin; D010100:Oxygen